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Abstract: The GOLDILOKs® (Genomic and Ontogeny-Linked Dose Individualization and cLinical
Optimization for KidS) Clinic aims to provide families and physicians with data to make more
informed decisions with regard to pharmacological therapy by using innovative therapy and genomic
technologies. The objectives are two-fold: (1) To describe the utility of the GOLDILOKs® Clinic
to referring prescribers by evaluating the type of referrals made to the GOLDILOKs® Clinic and
(2) to assess the most often utilized technologies (e.g., genotyping) completed to formulate therapy
recommendations. Patient data from July 2010 to June 2016 was retrospectively reviewed following
Institutional Review Board (IRB) approval. The GOLDILOKs® Clinic evaluated 306 patients and
had increases in annual referrals from 14 in 2010–2011 to 84 in 2016–2017. The children that were
referred were predominately Caucasian (82%) and male (59%) with an average age of 12.4 ± 5.9 years.
Subspecialty versus primary care referrals accounted for 82% and 18% of referrals, respectively.
Adverse drug reactions (n = 166) and poor medication response (n = 179) were the major reasons
for referral. However, it must be noted that patients could have multiple reasons for referral.
Pharmacogenetic results were extensively used to provide guidance for future therapy in patients
with medication-related problems. Genotyping of drug metabolizing enzymes and drug target
receptors was performed in 221 patients (72.2%). Recommendations were fully accepted by 63% and
partially accepted by 22% of internal provider referrals.
Keywords: pharmacogenetics; personalized medicine; pediatrics; multidisciplinary clinic; adverse
drug reaction

1. Introduction
Precision medicine is a concept that incorporates high throughput data to characterize diagnosis
and optimize therapeutics, with the intent to improve patient health outcomes [1,2]. With this
in mind, the goal of a precision medicine clinic from the therapeutic perspective of patient care
is to determine the right medication and dose for each individual patient instead of utilizing a
“one size fits all” approach. A common approach of precision medicine clinics has been to focus
on pharmacogenetic information to put an end to the trial and error process of finding the best
medication. However, personalizing medicine for a patient must also incorporate knowledge of
the pharmacologic and pharmacokinetic (PK) properties of medications. The medication–response
relationship is multifactorial, including compliance, absorption, distribution, receptor interaction,
metabolism, elimination, and a clear diagnosis with appropriate therapy. All these variables need
to be considered when providing precision medicine. Understanding what might be the perfect
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medication for a child is not as simple as ordering the pharmacogenetic tests associated with medication
metabolism. Genes code for both PK (e.g., drug metabolizing enzymes) and pharmacodynamic (PD)
targets (e.g., drug transporters or target receptors). Genetic variations can lead to differences in
drug efficacy or the potential for adverse reactions in different patients. Choice of therapy for a
particular patient therefore has to take into consideration multiple potential variations related to
different combinations of these variations. Likewise, understanding the subtleties of different drug
formulations can improve the choice of alternative products that may optimize clinical effects, while
minimizing side effects.
Several technologies are available to aid in individualizing medicine, including single nucleotide
polymorphism genotyping, estimation of genotype via a phenotype study, and measurement of
drug concentrations in the body to understand drug disposition in a particular patient. Ideally,
pharmacogenetic testing would be performed preemptively, as opposed to reactionary testing to
guide future therapies. However, reactionary testing may be more prominent due to the challenges of
widely implementing pharmacogenetic testing and the relatively new availability of this testing in the
outpatient clinical setting [3–5]. There are examples in pediatric cardiology, pediatric oncology, as well
as psychiatry, where pharmacogenetic information can be utilized to personalize patient care [6–10].
This brief report will provide an overview of the GOLDILOKs® (Genomic and Ontogeny-Linked Dose
Individualization and cLinical Optimization for KidS) Clinic at Children’s Mercy Hospital, which was
established in 2010 as part of our initiative to integrate the advancements of genomic technologies and
pharmacogenetic research directly into pediatric patient care. Our approach is to consider additional
factors which may impact the medication–response relationship and to incorporate PK, PD, and
pharmacogenetic information when providing medication therapy recommendations.
2. Materials and Methods
A retrospective review of the GOLDILOKs® Clinic database at Children’s Mercy Hospital (CMH)
was conducted following approval from the Children’s Mercy Institutional Review Board (IRB)
(ID#15050182, approved 27 September 2015). All patients referred to the GOLDILOKs® Clinic are
entered into our clinic database and are seen without exclusion. Patients who do not show for the
appointment are still included in the database with the information available to us at the time of initial
referral. Demographic information for all patients in the GOLDILOKs® Clinic database between 1 July
2010 and 30 June 2016 were included in this analysis. Patients who did not show for the clinic visit
were counted in the total number of patients scheduled. Patients seen after 30 June 2016 were excluded
from this description of the GOLDILOKs® Clinic.
GOLDILOKs® Clinic Operations (Figure 1): Patients are referred to the GOLDILOKs® Clinic
via multiple processes, which include internal and external healthcare providers in both medical
subspecialties and primary care settings, as well as self-referrals by the patient’s legal guardian. Upon
receipt of the referral, the clinic’s nurse coordinator contacts the family to determine the reason for
referral and to obtain consent from the legal guardian to transfer all medical records pertinent to the
reason for referral, including prior medications and the corresponding response to therapy. Once all the
pertinent medical history is received for review, the family is contacted to schedule the initial clinic visit.
The past medical history, medication history, and response to therapy is then reviewed and compiled
by the GOLDILOKs® Clinic’s clinical pharmacist or staff physicians. This information is presented
at the weekly multidisciplinary GOLDILOKs® Clinic’s team meeting. The multidisciplinary team
includes nurses, pharmacists, physicians, clinical pharmacologists, clinical pharmacology fellows, and
research scientists (Ph.D.). Together the team reviews the patient’s past medical history to determine
an appropriate action plan for the patient’s clinic visit and if pharmacogenomic testing or any further
laboratory tests may be beneficial. Patients are then seen in the clinic by the clinical pharmacist and a
physician, where the past medical history is confirmed with the family, the patient is examined, and
pharmacogenomic testing or other laboratory tests are completed if required. Patient information is
collected and stored in the GOLDILOKs® Clinic database which is maintained in a Research Electronic
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1. GOLDILOKs® (Genomic
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KidS) Clinic flow chart.
Clinic nurse contacts the family and determines reason for referral. Consent is obtained to transfer all

Referral received

medical records pertinent to the reason for referral. When all records have been received, the appointment
is scheduled.
a. New patients: The past medical history, medication history, and response to therapy is reviewed and

Preparation for visit

compiled by the GOLDILOKs® Clinic’s clinical pharmacist or staff physician.
b. Follow-up patients: Test results reviewed and previous medications and responses reviewed. Potential
recommendations complied.
Patients for that week’s clinic are presented to the team:

Weekly GOLDILOKs®
team meeting

a. New patients: Review the past medical history to determine an appropriate action plan for
the patient’s clinic visit and if pharmacogenomic testing or any further laboratory tests may be
beneficial.
b. Follow-up patients: Discuss test results and determine medication options for the referring
physician to consider.

GOLDILOKs® Clinic visit

a. New patients seen by the clinical pharmacist and a physician where the past medical history
is confirmed with the family, the patient is examined, and pharmacogenomic testing or other
laboratory tests are completed if required.
b. Follow-up patients: Test results explained to families along with potential medication
recommendations their care provider might consider.

Clinic letters sent

Letter is sent to referring provider following the visit:
a. New patient’s letters provide a detailed medication history, immediate recommendations if
possible, and the pending laboratory tests ordered, along with explanation of potential benefit
to the patient for the test ordered.
b. Follow-up patient’s letters: Provide an explanation of the test results along with implications
to the patient’s future care.

Clinical and laboratory data included in this analysis were extracted from the GOLDILOKs® Clinic
Figure 1. GOLDILOKs® (Genomic and Ontogeny-Linked Dose Individualization and cLinical
database, which is maintained in REDcap. Data collection included basic demographic data; underlying
Optimization for KidS) Clinic flow chart.
diagnoses; reason for referral to the clinic; referring physician information; medications that the patient is
on at the time of the visit; prior medications for which there were adverse reactions or poor response to®
Clinical and laboratory data included in this analysis were extracted from the GOLDILOKs
treatment; pharmacogenetic testing and other laboratory, personalized medicine, or diagnostic tests
Clinic database, which is maintained in REDcap. Data collection included basic demographic data;
ordered; and recommendations made to the referring physician. If the patient was referred by a CMH
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defined as all recommendations made were accepted. Partial acceptance was defined as some of the

or diagnostic tests ordered; and recommendations made to the referring physician. If the patient was
referred by a CMH provider, a chart review was conducted within 6 months of the visit to determine if
there was acceptance, partial acceptance, or non-acceptance of the recommendations by the referring
provider. Acceptance was defined as all recommendations made were accepted. Partial acceptance
was defined as some of the recommendations were accepted and non-acceptance was defined as none
of the recommendations were accepted.
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Descriptive statistics were used to describe the referrals made to the GOLDILOKs® Clinic and to
describe the laboratory evaluation or testing completed to help provide recommendations for altering
therapy to the referring health care provider.
3. Results
Since the start of the GOLDILOKs® Clinic in July 2010, there were 315 referrals placed (initial
clinic visit), 164 follow-up visits, and 5 patients who were seen for a third time. Taking into account
duplicate patients and rescheduling, the total number of individuals actually seen between 1 July
2010 and 30 June 2016 was 306. The number of patients seen during each year of clinic operation is
presented in Table 1. The patients seen were predominately male (59%). Self-reported race included
Caucasian (n = 254, 81.9%), multiracial (n = 18, 5.8%), African American (n = 15, 4.8%), Asian (n = 12,
3.8%), Hispanic (n = 7, 2.3%), Middle Eastern (n = 2, 0.6%), and other (n = 2, 0.6%). The average age
was 12.4 ± 5.9 years. Fifty-three patients were adopted from the United States (n = 41), China (n = 8),
Korea (n = 1), and unknown countries (n = 3). Fourteen patients were initially seen as an inpatient
consult with follow-up appointments in clinic.
Table 1. Number of patients per each year of clinic.
Year

No. of Initial Clinic Visits Scheduled

No. of Follow-up Visits

1 July 2010–30 June 2011
1 July 2011–30 June 2012
1 July 2012–30 June 2013
1 July 2013–30 June 2014
1 July 2014–30 June 2015
1 July 2015–30 June 2016

14
44
45
52
76
84

0
20
24
21
35
64

315 total referrals/visits since starting clinic. Five patients had 3 visits since the start of clinic. There were 152 single
visits. Four patients did not show up for the initial visit.

Referrals to the GOLDILOKs® Clinic were predominately made by pediatric medical
subspecialists compared to pediatric primary care providers (n = 257 (82%) vs. n = 57 (18%),
respectively). One patient was noted to be a self-referral. Additionally, the majority of referrals
were made by care providers within the host institution. Among the subspecialty of care providers,
psychiatry represented the majority of referrals at 73% (Table 2). Referrals included evaluation of
multiple adverse drug reactions (166/401, 41%), poor therapeutic response/tachyphylaxis to prescribed
medications (180/401, 45%), genotyping requested by the physician or the family (24/401, 6%),
interpretation of genotyping previously obtained (14/401, 3.5%), concern for potential QT interval
prolongation due to a need for anxiolytics or antidepressants (3/401, 0.7%), concern for potential
drug–drug interactions given need for many medications (2/401, 0.5%), previously seen and genotyped
but continues to struggle (2/401, 0.5%), concern for therapy initiation based on family history of adverse
reactions (1/401, 0.2%), and other reasons (9/401, 2%) (Table 3). Some patients had more than one
reason for referral (n = 106). The most common underlying diagnoses included Attention Deficit
Hyperactivity Disorders (n = 164), anxiety disorders (n = 132), Autism Spectrum Disorders/Pervasive
Developmental Disorder (n = 84), gastrointestinal illnesses (n = 70), tic disorders (n = 50), depression
(n = 46), seizures (n = 45), sleep disorders (n = 26), and syndromes/chromosomal anomalies (n = 35).
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Table 2. Referrals to a GOLDILOKs® Clinic.

Provider who initiated referral

Primary Care Provider: 57 (18.1%)
Internal providers: 9 (16%)
External providers: 48 (84%)
Subspecialist: 257 (81.6%)
Internal providers: 223 (87%)
External providers: 34 (13%)
Self: 1 (0.3%)

Subspecialist area of practice

Psychiatry/psychology: 188
Neurology: 18
Gastroenterology: 16
Pulmonology/sleep medicine: 8
Dermatology: 5
Endocrinology: 4
Genetics: 4
Beacon clinic: 3
Rheumatology: 2
Allergy/immunology: 2
Other: 7

Table 3. Other reasons for GOLDILOKs® referral.
1. Help transitioning into adult care;
2. To help determine appropriate medication for anxiety and depression;
3. Use of octreotide to assist in control of weight gain;
4. Increased phenobarbital levels, concern for altered phenobarbital metabolism;
5. Evaluation of chronic inflammatory process and medication responses;
6. Evaluation of recurrent hypothermia and medications that may help with thermoregulation;
7. Patient’s family contacted clinical pharmacology to discuss the safety of the prolonged use of sedatives and
paralytics because we have assisted with tapering his sedatives during previous hospitalizations. Concerns
due to multiple planned future surgeries;
8. Poor tolerance of Oral Iron products. Need recommendations for intravenous dose for Restless Leg
Syndrome in pediatric patient;
9. Evaluation of medications to avoid Opsoclonus-Myoclonus Syndrome (OMS).

The mean number of medications taken per patient upon initial evaluation in the clinic was
5.2 ± 3.8 (median: 5, mode: 4, range: 0–25). The top 15 medications were Melatonin (n = 74),
guanfacine (n = 68), cetirizine (n = 45), methylphenidates (n = 42), fluticasone (n = 41), amphetamine
salts (n = 39), clonidine (n = 39), polyethylene glycol 3350 (n = 39), montelukast (n = 34), albuterol
(n =3 3), fluoxetine (n = 33), sertraline (n = 30), aripiprazole (n = 26), dexmethylphenidate (n = 23),
and trazodone (n = 22). The most commonly used antiepileptics were topiramate, valproic acid, and
levetiracetam. Twenty-three patients were on no medications at the time of the first clinic appointment.
The mean number of adverse reactions to medications per patient at the first clinic visit was 5 ± 4.1
(median: 4, mode: 3). The number of prior medication adverse reactions at the time of the first visit
was variable, ranging from 0 to 34 (Figure 2).
Genotyping was obtained to assist in medication recommendations in 221 patients (72.2%).
Cytochrome P450 2D6 (CYP2D6) genotyping was the most common gene tested (99%), followed by
Cytochrome P450 2C19 (CYP2C19) (88%) and the serotonin 2A and 2C receptors (HTR2C and HTR2A)
(76%). Other genotyping tests performed included CYP2C9 (14%); CYP3A5 (1%); SLC6A4 (25%);
the gene that encodes for the serotonin reuptake transporter (18%); DRD3, the gene that encodes the
dopamine 3 receptor (14%); and DRD4, the gene that encodes for the dopamine 4 receptor (12%).
Figures 3 and 4 provide the phenotype predictions, based solely on the genotype results, for the
CYP enzymes most commonly tested in the GOLDILOKs® Clinic and the serotonin 2A/2C receptor
phenotype predictions in our population.
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test (n = 17), thyroid studies (n = 11), therapeutic drug monitoring (n = 6, oxcarbazepine × 1, lithium × 2,
obtained included: Complete blood count (n = 32), iron studies (n = 26), basic metabolic panel (n = 15),
valproic acid × 1, clozapine × 1, clonidine × 1), area under the curve assessment × 2 (phenobarbital, valproic
liver function test (n = 17), thyroid studies (n = 11), therapeutic drug monitoring (n = 6, oxcarbazepine
acid), and phenotype evaluation (n = 2) which predicted cytochrome P450 2D6 function by using
× 1, lithium × 2, valproic acid × 1, clozapine × 1, clonidine × 1), area under the curve assessment × 2
dextromethorphan (1 = normal metabolizer, 1 = indeterminate). Forty‐nine other miscellaneous tests were
(phenobarbital, valproic acid), and phenotype evaluation (n = 2) which predicted cytochrome P450
ordered.
For patients whose prescribing doctors were internal to CMH, chart review found that 63% of
recommendations made to the referring physician were accepted, with an additional 22% of
recommendations partially accepted. Recommendations were not accepted in 14% of the patients referred
to the clinic. Lastly, for 1% of the patients, data were not obtained due to lost to follow‐up when the patient
switched to a provider outside of CMH.
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2D6 function by using dextromethorphan (1 = normal metabolizer, 1 = indeterminate). Forty-nine
other miscellaneous tests were ordered.
For patients whose prescribing doctors were internal to CMH, chart review found that 63%
of recommendations made to the referring physician were accepted, with an additional 22% of
recommendations partially accepted. Recommendations were not accepted in 14% of the patients
referred to the clinic. Lastly, for 1% of the patients, data were not obtained due to lost to follow-up
when the patient switched to a provider outside of CMH.
4. Discussion
To our knowledge, this is the first report describing an outpatient pediatric precision medicine
clinic in which the entire medication–exposure relationship is assessed. Since 2010, we have
successfully implemented a novel multidisciplinary pediatric personalized medicine clinic in which
the patients have access to recommendations and education from pediatricians, pharmacists, clinical
pharmacologists, researchers, and those in other disciplines working together to provide medication
therapy recommendations to referring providers to address this need. Our clinic has expanded
from 14 referrals during the first year of operation to 84 referrals during the sixth year of operation.
Multiple variables are considered including PK, PD, and pharmacogenetic testing when appropriate.
The majority of referrals to the GOLDILOKs® Clinic were to advise in scenarios where patients had
experienced multiple adverse drug reactions (ADRs), poor therapeutic response, or tachyphylaxis
to prescribed medications. Referring care providers and parents appear particularly interested in
implementing pharmacogenetic testing to assist in developing treatment plans for children. However,
pharmacogenetic testing is not the only resource a personalized/precision medicine clinic might use.
The most common reasons for referral to our clinic were history of multiple adverse drug reactions
and poor therapeutic response/tachyphylaxis to prescribed medications. To investigate the cause(s)
of ADR or treatment failure, we conducted a thorough chart review and considered factors such
as compliance, absorption, distribution, drug-receptor interaction, metabolism, elimination, and
diagnosis. In addition, a patient and family interview is completed to understand the presentation
and timeline of the ADR. A thorough medication history is obtained, including a complete list
of prescription and over the counter medications that the patient is or was taking, given that the
likelihood of developing an adverse interaction increases with the number of drugs prescribed [11,12].
For instance, data suggest that if five drugs are given simultaneously, the chance of an adverse
interaction occurring is approximately 50% [13]. The patients referred to this clinic were typically on
several medications (mean (SD) = 5.2 (3.8)) with a history of multiple prior adverse reactions (mean
(SD) = 5 (4.1)). As such, our clinic population is at high risk for morbidity from ADRs based on the
polypharmacy seen.
ADRs are of two types: Pharmacologic, dose-related (Type-A) and idiosyncratic, non-dose related
(Type-B). Type-A ADRs, the most common reactions, are dependent on the dose and reversible with
dose reduction [14]. As such, pharmacogenetic testing might help in the correlation of ADRs with
a medication. Besides dose, there are multiple other factors that can contribute to Type-A ADRs,
including formulation variations, PK variation, and drug–drug interactions, which we also take into
account during each of our clinic visits with a patient. Type-B reactions may be impacted by the
body’s drug metabolizing system due to potential accumulation of toxic metabolites [15] which may
contribute to ADRs. Additionally, Type-B reactions are also thought to be due to the immune system,
as not all Type-B reactions can be simply explained by alterations in metabolism. Pharmacogenetic
testing for variations in drug metabolism can help explain ADRs with an estimated 15%–30% of
variable drug response due to genetic polymorphisms [16,17]; however, it is important to note that
the majority of polymorphisms are rare with minor allele frequencies (<1%) [18]. In our clinic, this is
evident based on the limited number of poor and ultra-rapid metabolizers (Figure 3), despite the high
number of ADRs (mean 5 ± 4.1). Therefore, while pharmacogenetic variability may explain some of
the ADRs observed in our population, it would appear that, for the majority of patients, their reason
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for drug response/non-response is likely multi-factorial and requires multidisciplinary collaboration
to interpret and guide therapy. PD (drug-receptor interactions) variability also needs to be considered
when assessing medication response (Figure 4); unfortunately, current data related to the PD response
is not as extensive as available PK data. In addition to understanding the pharmacogenetics factors
contributing to ADRs in our clinic population, this multidisciplinary clinic serves to address all possible
contributing factors to ADRs.
Genotyping is often requested not only to understand why the child has frequent ADRs to
medications, but also to choose initial therapies, or to re-challenge the child with medication that
will be less likely to result in a repeat ADR. In our clinic, pharmacogenetic testing was stated at a
reason for referral ~6% of the time. Twenty-four (8%) family requests for genotyping were also noted.
Consistent with available literature, parents are concerned that medications have significant side
effects [19]. There is concern that giving medications to treat behavior problems in pediatric patients
will have a long-term negative impact on development. Additionally, medications can impact mood
and personality, with parents often describing a flat, “zombie”-like effect which may decrease the
utilization of medications or delay treatment of the underlying behavior problem [20]. Based on a
survey of public attitudes [21], pharmacogenetics testing is desirable for a variety of reasons, including
prediction of drug effectiveness, initial dose determination, and concerns related to adverse drug
reactions. In this survey, participants were interested in pharmacogenetic testing to predict mild
(73 ± 3.29%) or serious (85 ± 2.91%) side effects, to use this information to guide dosing (91%), or to
assist with drug selection (92%). In our clinic, we suspect that pharmacogenetic testing with evaluation
by an integrative care team was sought out by providers and families based on previous experience
with medication options and to support future plans for care. Thus, parents and prescribers seek out
additional information such as pharmacogenetic testing that might provide insight into the next steps
for medication therapy.
Anecdotally, parents express concerns about a trial-and-error approach for determining the correct
medication for their child and, if given the option, would rather make more informed decisions for their
child’s care through pharmacogenetic testing. Of interest, 23 referred patients were on no medications
at the time of their initial visit but were considering medications in the future. Additionally, the
percentage of adopted children who presented to the clinic (53/306, 17.3%) is substantially higher than
the national average of 7% according to the 2010 US Census [22]. Adoptive parents are unlikely to
have knowledge of prior family history of their adopted child, knowledge which could have assisted
providers with choosing initial medication management. For these families, pharmacogenetic testing
might offer some confidence in the choice of medication. This is speculative and requires further
investigation, especially to determine if the patient benefited from less medication adjustments or
avoided side effects due to preemptive pharmacogenetic testing.
Pharmacogenetic testing is frequently sent to commercial laboratories, which then provides the
pharmacogenetic results and some generic medication recommendations. However, determination of
the optimal medication for a patient is not as straightforward as would be anticipated, given the various
combinations of PK and PD related genes that need to be considered for each individual medication.
Another difficulty in utilizing the information is that the phenotype prediction provided on the reports
is based solely on the patient’s genotype and does not account for drug–drug interactions, drug–food
interactions, underlying illness, or ontogeny in the pediatric population, which can also impact the
patient’s phenotype. Additionally, for some drug–gene interaction pairs, guidelines such as those
available on www.pharmgkb.org or dosing information with the drug’s package insert may not be
available. Primary care providers are often not trained on the use of these panels, leaving providers
with additional questions but no easy access to answers. Thus, specialty precision medicine clinics
such as ours can help prescribers understand the reports more specifically to an individual patient.
As noted above, providers and families have sought out pharmacogenetic testing as a means to
determine the optimal medication for the patient. However, pharmacogenetic testing is not the only
tool utilized to provide precision therapeutics for children in our clinic because for many medications
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genotyping predicting response (PD) to the medication may not be available. Thus, our clinic also
takes into account other variables that might impact response to treatment such as compliance, drug
formulations, and medication history. For medications to be effective, patient compliance has to be
considered. Parental apprehensions regarding the necessity of medication impacted compliance such
that parents who expressed higher levels of skepticism towards a medication were more likely to have
poor adherence (p < 0.05) [23]. Conceivably, pharmacogenetic information may ease apprehension
toward future medications and possibly impact compliance, although this needs to be studied. In some
situations, PK information related to medication dosage forms may be more valuable compared
to pharmacogenetic results. For example, while there are companies offering pharmacogenetic
Attention Deficit Hyperactivity Disorder (ADHD) panels, results gained from this testing do not
provide providers with specific recommendations outlining which type of stimulant might be better for
the patient (amphetamine versus methylphenidate), because currently there are no pharmacogenetic
studies comparing the efficacy of different stimulants to each other. Current evidence related to
prediction of methylphenidate efficacy is predominately from non-randomized association studies
in which genotypes are sorted by response and non-response [24,25]. Multiple reviews comparing
the pharmacokinetics of the available stimulant formulations have been published and are utilized
in our clinic to help provide recommendations related to the stimulant medications [26,27]. Use of
this information can help tailor the ADHD medication regimens for a patient by selection between
the various short-acting and long-acting formulations and assessing of the peak time of day with
poor symptom control. Another benefit of our clinic is that we provide the primary prescriber with
an extensive pharmacologic review and evaluation of previous medication exposures and responses
from all the patients’ multiple providers, past and present, to the extent that the records are made
available to us. Insight provided by such an extensive medication history from outside reviewers may
help providers consider medications for re-challenges and other options. Finally, multidisciplinary
precision medicine clinics such as ours can help prescribers with other medication related dilemmas and
interesting therapeutic challenges. For example, our clinic has assisted with subcutaneous octreotide
and intranasal oxytocin for a patient with panhypopituitarism and intravenous iron infusions for
patients with restless leg syndrome and insomnia who were unable to tolerate multiple different
enteral iron preparations or lack of success replacing ferritin with confirmed enteral compliance.
As our clinic is a consultative service clinic to long-term care providers, the ability to directly assess
the outcomes of all our recommendations is difficult, as we do not have access to patient outcomes
long-term. This is a retrospective, descriptive study of the implementation of a GOLDILOKs® clinic
and assists with understanding the reasons for which providers and families request genotyping. Thus,
moving forward, we intend to use this information to effectively choose outcome parameters that
might be implemented to determine the benefits to the patient and the cost effectiveness of clinics such
as ours. However, for referring prescribers within our health care system, we were able to determine
that about 63% of recommendations made were accepted, with an additional 22% of recommendations
partly accepted. Partly accepted means that some of the recommendations made were accepted. This is
likely because we provide multiple options simultaneously for consideration to the referring physician
who follows the patient long-term. Given the multiple options that might be appropriate to a patient’s
care and because frequently multiple medication changes are not made simultaneously, in order to
better access the clinical impact of the medication change in a particular patient, we would anticipate
that not all the recommendations would be completely accepted at the time the chart was reviewed.
5. Conclusions
Pediatric personalized medicine encompasses additional challenges as children undergo dynamic
growth and development and have demonstrated different responses to drugs. A multidisciplinary
pediatric precision medicine which can consider PK, PD, and pharmacogenetic factors can help
providers and families find treatment options for children who have experienced poor medication
response and adverse reactions. Since the medication–response relationship is multifactorial,
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it will be important to further assess the benefits of a precision medicine clinic, including newer
technologies such as pharmacogenetic testing. The pediatric personalized medicine clinic model
is likely generalizable and applicable at academic hospitals to select patients in need of additional
resources. Our paper shows there is a need and demand for evaluation and follow-up within a formal
clinic setting. Continued research is needed to determine whether these findings translate to improved
outcomes, streamlined medication selection, fewer adverse drug reactions, patient satisfaction, and
provider satisfaction.
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